<DOC>
	<DOCNO>NCT00627692</DOCNO>
	<brief_summary>The purpose study determine whether prucalopride safe effective treatment constipation elderly subject live nursing facility . Hypothesis : Prucalopride dose 4 mg daily safe well tolerate elderly subject live nursing facility .</brief_summary>
	<brief_title>Evaluation Safety Tolerability Prucalopride Constipated Elderly Subjects Living Nursing Facility</brief_title>
	<detailed_description>This multicenter , Phase II , dose-escalation trial 4 week double-blind , placebo-controlled treatment period . There four treatment cohort ( 0.5 mg , 1 mg , 2 mg , 4 mg ) 25 subject . The first cohort 25 subject randomly assign receive either 0.5 mg R108512 placebo 4 1 ratio , respectively , four week . After two week treatment , safety tolerability dose evaluate subject independent ( external ) safety committee . If , completion treatment , safety committee grant approval proceed high dose , second cohort randomly assign receive either 1 mg R108512 placebo four week . In likewise manner , dose evaluate safety tolerability next cohort treat high dose . No subject participate one treatment cohort . Subjects instructed change diet lifestyle trial . Subjects allow continue use routine stool softener fiber supplement trial ; however , exist stimulant osmotic laxative medication withdrawn . If , trial , subject complete bowel movement three consecutive day , he/she allow use his/her usual stimulant osmotic laxative enema rescue medication . No laxatives enemas use within 24 hour 24 hour start double-blind treatment .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Male female patient least 65 year age ( upper age limit ) . 2 . History constipation . i.e. , patient receive treatment constipation time 4 week ( 28 day ) precede entry study , include fibre/bulk forming supplement . 3 . The patient live nursing facility . 4 . The patient clinically stable . 5 . The patient able take oral medication . 6 . The patient continent bowel majority time . 7 . The patient able reliably communicate AEs . 8 . The patient provide inform consent , sign patient legally acceptable representative investigator . 1 . Patients know HIV positive AIDS . 2 . Patients actively treat Propulsid ( cisapride ) cancer chemotherapy hormonal agent . 3 . Patients significantly impair renal function , i.e. , creatinine clearance &lt; 30 mL/min use Cockcroft Gault formula : Males : CLCR = [ ( 140age ) x ( weight kg ) ] / 72 x ( SCR ) . Females : CLCR = male value x 0.85 Because calculate value creatinine clearance could artificially high serum creatinine concentration low , patient serum creatinine &lt; 0.5 mg/dL exclude study . 4 . Patients receive investigational drug 30 day precede study . 5 . Patients previously receive either R093877 R108512 .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Constipation elderly patient</keyword>
</DOC>